0001000228-24-000025 | 10-Q | XBRL Viewer

Print Document

Business Acquisitions (Tables) - Biotech Dental [Member]	3 Months Ended
	Mar. 30, 2024
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Preliminary Allocation as of July 1, 2023 Measurement Period Adjustments Allocation as of March 30, 2024 Acquisition consideration: Cash $ 216 $ - $ 216 Fair value of contributed equity share in a controlled subsidiary 25 - 25 Redeemable noncontrolling interests 182 - 182 Total consideration $ 423 $ - $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 78 $ (4) $ 74 Intangible assets 119 70 189 Other noncurrent assets 76 (7) 69 Current liabilities (50) (10) (60) Long-term debt (90) 17 (73) Deferred income taxes (38) (15) (53) Other noncurrent liabilities (16) (4) (20) Total identifiable net assets 79 47 126 Goodwill 344 (47) 297 Total net assets acquired $ 423 $ - $ 423
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 47 9 Trademarks / Tradenames 18 7 Product development 124 10 Total $ 189

Business Acquisitions	3 Months Ended
Business Acquisitions	Mar. 30, 2024
Business Acquisitions [Abstract]
Business Acquisitions	Note 6 – Business Acquisitions Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies. 2024 Acquisitions During the quarter ended March 30, 2024, we made acquisitions within the technology and value-added services segment. Our acquired ownership interest in these companies was 100 %. Total consideration for these acquisitions was $ 19 million. Net assets acquired primarily consisted of $ 8 million of goodwill and $ 12 million of intangible assets. The intangible assets acquired consisted of customer relationships and lists of $ 6 million, product development of $ 4 million, trademarks and tradenames of $ 1 million and non-compete agreements of $ 1 million. Weighted average useful lives for these acquired intangible assets were 10 years, 10 years, 5 years and 5 years, respectively. Goodwill is a result of the expected synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is deductible for tax purposes. The impact of these acquisitions, individually and in the aggregate, was not considered material to our condensed consolidated financial statements. 2023 Acquisitions Acquisition of Shield Healthcare On October 2, 2023 we acquired a 90 % voting equity interest in Shield Healthcare, Inc. (“Shield”), a supplier of homecare medical products delivered directly to patients in their homes, for preliminary consideration of $ 366 million (including cash paid of $ 307 million, deferred consideration of $ 22 million and redeemable noncontrolling interests of $ 37 million). Based in California, Shield expands our existing medical business by delivering a diverse range of products, including items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes. The accounting for the acquisition of Shield has not been completed in several respects, including but not limited to finalizing valuation assessments of accounts receivable, inventory, accrued liabilities and income and non-income based taxes. To assist in the allocation of consideration, we engaged valuation specialists to determine the fair value of intangible and tangible assets acquired and liabilities assumed. We will finalize the amounts recognized as the information necessary to complete the analysis is obtained. During the quarter ended March 30, 2024, we recorded immaterial measurement period adjustments, related primarily to operating leases. The pro forma financial information has not been presented because the impact of the Shield acquisition was immaterial to our consolidated financial statements. Acquisition of S.I.N. Implant System On July 5, 2023, we acquired a 100 % voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration of $ 329 million. Based in São Paulo, S.I.N. manufactures an extensive line of products to perform dental implant procedures and is focused on advancing the development of value-priced dental implants. S.I.N. recently expanded the distribution of its products into the United States and other international markets. The accounting for the acquisition of S.I.N. has not been completed in several respects, including but not limited to finalizing valuation assessments of accounts receivable, inventory, accrued liabilities and income and non-income based taxes. To assist in the allocation of consideration, we engaged valuation specialists to determine the fair value of intangible and tangible assets acquired and liabilities assumed. We will finalize the amounts recognized as the information necessary to complete the analysis is obtained. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. During the quarter ended March 30, 2024, we recorded insignificant measurement period adjustments, related primarily to deferred tax adjustments. The pro forma financial information has not been presented because the impact of the S.I.N. acquisition was immaterial to our consolidated financial statements. Acquisition of Biotech Dental On April 5, 2023, we acquired a 57 % voting equity interest in Biotech Dental (“Biotech Dental”), which is a provider of dental implants, clear aligners, individualized prosthetics and innovative digital dental software based in France. Biotech Dental has several important solutions for dental practices and dental labs, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience. The integration of Biotech Dental’s software with Henry Schein One’s industry-leading practice management software solutions will help customers streamline their clinical as well as administrative workflow for the ultimate benefit of patients. The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the Biotech Dental acquisition, including measurement period adjustments recorded through March 30, 2024: Preliminary Allocation as of July 1, 2023 Measurement Period Adjustments Allocation as of March 30, 2024 Acquisition consideration: Cash $ 216 $ - $ 216 Fair value of contributed equity share in a controlled subsidiary 25 - 25 Redeemable noncontrolling interests 182 - 182 Total consideration $ 423 $ - $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 78 $ (4) $ 74 Intangible assets 119 70 189 Other noncurrent assets 76 (7) 69 Current liabilities (50) (10) (60) Long-term debt (90) 17 (73) Deferred income taxes (38) (15) (53) Other noncurrent liabilities (16) (4) (20) Total identifiable net assets 79 47 126 Goodwill 344 (47) 297 Total net assets acquired $ 423 $ - $ 423 Goodwill is a result of expected synergies that are expected to originate from the acquisition as well as the expected growth potential of Biotech Dental. The acquired goodwill is deductible for tax purposes. During the quarter ended March 30, 2024 we finalized our accounting for the acquisition and recorded measurement period adjustments related primarily to the completion of the intangibles valuation, including adjustments to intangibles, deferred tax and certain other assets and liabilities. The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Biotech Dental: 2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 47 9 Trademarks / Tradenames 18 7 Product development 124 10 Total $ 189 The pro forma financial information has not been presented because the impact of the Biotech Dental acquisition was immaterial to our condensed consolidated financial statements. Other 2023 Acquisitions During the year ended December 30, 2023, in addition to those noted above, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest ranged between 51 % to 100 %. During the quarter ended March 30, 2024, we recorded an adjustment of $ 15 million, within the selling, general and administrative line in our condensed consolidated statements of income, representing a change in the fair value of contingent consideration related to a 2023 acquisition. During the three months ended March 30, 2024 we completed accounting for certain acquisitions that occurred in the year ended December 30, 2023. In relation to these acquisitions, we did not record material adjustments in our condensed consolidated financial statements relating to changes in estimated values of assets acquired, liabilities assumed and contingent consideration assets and liabilities. The pro forma financial information for our 2023 acquisitions has not been presented because the impact of the acquisitions was immaterial to our condensed consolidated financial statements. Acquisition Costs During the three months ended March 30, 2024 and April 1, 2023 we incurred $ 2 million and $ 7 million in acquisition costs, which are included in “selling, general and administrative” within our condensed consolidated statements of income.

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 30, 2024
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended March 30, April 1, 2024 2023 Basic 128,720,661 131,365,789 Effect of dilutive securities: Stock options and restricted stock units 1,048,919 1,674,097 Diluted 129,769,580 133,039,886
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended March 30, April 1, 2024 2023 Stock options 419,139 422,190 Restricted stock units 245,667 18,305 Total anti-dilutive securities excluded from earnings per share computation 664,806 440,495

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	664,806	440,495
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	419,139	422,190
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	245,667	18,305

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Supplemental Cash Flow Information [Abstract]
Interest	$ 26	$ 13
Income taxes	21	21
Non-cash net unrealized gains related to foreign currency hedging activities	$ 15	$ (4)

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 30, 2024
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 12 – Stock-Based Compensation Stock-based awards are provided to certain employees under our 2020 Stock Incentive Plan and to non-employee directors under our 2023 Non-Employee Director Stock Incentive Plan (formerly known as the 2015 Non- Employee Director Stock Incentive Plan) (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs and in 2022, when we granted time-based and performance-based RSUs, as well as non- qualified stock options. For our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based and performance-based RSUs. Our non-employee directors receive equity-based awards solely in the form of time-based RSUs. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted to our non-employee directors primarily include 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. For all RSUs, we estimate the fair value based on our closing stock price on the grant date. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, amortization expense recorded for acquisition-related intangible assets (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), and unforeseen events or circumstances affecting us. Over the performance period, the number of RSUs that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense is based on our actual performance metrics as defined under the 2020 Stock Incentive Plan. Stock options are awards that allow the recipient to purchase shares of our common stock after vesting at a fixed price set at the time of grant. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of term and term acceleration upon certain events. Compensation expense for stock options is recognized using a graded vesting method. We estimate grant date fair value of stock options using the Black-Scholes valuation model. During the three months ended March 30, 2024, we did no t grant any stock options. Our condensed consolidated statements of income reflect pre-tax share-based compensation expense of $ 8 million and $ 10 million for the three months ended March 30, 2024 and April 1, 2023. Total unrecognized compensation cost related to unvested awards as of March 30, 2024 was $ 120 million, which is expected to be recognized over a weighted-average period of approximately 2.7 years. Our condensed consolidated statements of cash flows present our stock-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented. There were no cash benefits associated with tax deductions in excess of recognized compensation for the three months ended March 30, 2024 and April 1, 2023. We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant that most closely aligns to the expected life of options. The six - year expected life of the options was determined using the simplified method for estimating the expected term as permitted under Staff Accounting Bulletin Topic 14. The following table summarizes the stock option activity for the three months ended March 30, 2024: Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,078,459 $ 71.46 Granted - - Exercised (21,570) 62.71 Forfeited (897) 82.62 Outstanding at end of period 1,055,992 $ 71.63 7.3 $ 8 Options exercisable at end of period 908,836 $ 69.49 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 147,110 $ 84.84 8.0 $ - The following tables summarize the activity of our unvested RSUs for the three months ended March 30, 2024: Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 432,350 76.56 450,333 76.81 Vested (307,839) 62.51 (6,432) 63.01 Forfeited (6,021) 81.48 (6,431) 83.07 Outstanding at end of period 1,773,883 $ 73.19 $ 75.52 646,212 $ 75.68 $ 75.52

Segment Data (Tables)	3 Months Ended
Segment Data (Tables)	Mar. 30, 2024
Segment Data [Abstract]
Business segment information	Three Months Ended March 30, April 1, 2024 2023 Net sales: Health care distribution (1) Dental $ 1,914 $ 1,898 Medical 1,041 971 Total health care distribution 2,955 2,869 Technology and value-added services (2) 217 191 Total $ 3,172 $ 3,060 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins, and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended March 30, April 1, 2024 2023 Operating Income: Health care distribution $ 126 $ 145 Technology and value-added services 24 30 Total $ 150 $ 175

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 84		$ 89	$ 86
Contract with Customer, Liability, Noncurrent	8		$ 9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 36	$ 35

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 84	$ 83
Inventory, reserves	$ 188	$ 192
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	128,480,909	129,247,765
Variable Interest Entity, Primary Beneficiary [Member] \| Recourse [Member]
Stockholders' equity:
Liabilities of VIE	$ 300	$ 210
Asset Pledged as Collateral [Member] \| Variable Interest Entity, Primary Beneficiary [Member]
Stockholders' equity:
Pledged assets	$ 497	$ 284

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 17 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the three months ended March 30, 2024 and April 1, 2023, we recorded $ 8 million and $ 8 million, respectively, in connection with costs related to this royalty agreement. As of March 30, 2024 and December 30, 2023, Henry Schein One, LLC had a net payable balance to Internet Brands of $ 3 million and $ 1 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other within our condensed consolidated balance sheets. We have interests in entities that we account for under the equity accounting method. In our normal course of business, during the three months ended March 30, 2024 and April 1, 2023, we recorded net sales of $ 12 million and $ 8 million respectively, to such entities. During the three months ended March 30, 2024 and April 1, 2023, we purchased $ 3 million and $ 2 million respectively, from such entities. At March 30, 2024 and December 30, 2023, we had an aggregate $ 31 million and $ 32 million, respectively, due from our equity affiliates, and $ 6 million and $ 5 million, respectively, due to our equity affiliates. Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from less than one month to 17 years. As of March 30, 2024, current and non-current liabilities associated with related party operating leases were $ 5 million and $ 22 million, respectively. At March 30, 2024 related party leases represented 6.7 % and 8.2 % of the total current and non-current operating lease liabilities, respectively. At December 30, 2023 related party leases represented 6.3 % and 7.4 % of the total current and non-current operating lease liabilities, respectively.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Net Sales from Contracts with Customers	3 Months Ended
Net Sales from Contracts with Customers	Mar. 30, 2024
Net Sales from Contracts with Customers [Abstract]
Net sales from Contracts with Customers	Note 4 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 30, 2023. Disaggregation of Net Sales The following table disaggregates our net sales by reportable and operating segment and geographic area: Three Months Ended March 30, 2024 North America International Global Net sales: Health care distribution Dental $ 1,103 $ 811 $ 1,914 Medical 1,014 27 1,041 Total health care distribution 2,117 838 2,955 Technology and value-added services 189 28 217 Total net sales $ 2,306 $ 866 $ 3,172 Three Months Ended April 1, 2023 North America International Global Net sales: Health care distribution Dental $ 1,144 $ 754 $ 1,898 Medical 951 20 971 Total health care distribution 2,095 774 2,869 Technology and value-added services 166 25 191 Total net sales $ 2,261 $ 799 $ 3,060 Contract Liabilities At March 30, 2024, December 30, 2023, and December 31, 2022, the current and non-current contract liabilities were $ 84 million and $ 8 million; $ 89 million and $ 9 million; and $ 86 million and $ 8 million, respectively. During the three months ended March 30, 2024, we recognized, in net sales, $ 36 million of the amount that was previously deferred at December 30, 2023. During the three months ended April 1, 2023, we recognized in net sales $ 35 million of the amounts that were previously deferred at December 31, 2022. Current contract liabilities are included in accrued expenses: other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	147,110
Weighted Average Exercise Price \| $ / shares	$ 84.84
Weighted Average Remaining Contractual Life (in years)	8 years
Intrinsic Value Per Share \| $	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Comprehensive Income	3 Months Ended
Comprehensive Income	Mar. 30, 2024
Comprehensive Income [Abstract]
Comprehensive Income	Note 14 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income and are recorded directly to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: March 30, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (42) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (232) $ (188) Unrealized loss from hedging activities (2) (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (239) $ (206) Total Accumulated other comprehensive loss $ (282) $ (239) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended March 30, April 1, 2024 2023 Net income $ 98 $ 128 Foreign currency translation gain (loss) (54) 25 Tax effect - - Foreign currency translation gain (loss) (54) 25 Unrealized gain (loss) from hedging activities 15 (4) Tax effect (4) 1 Unrealized gain (loss) from hedging activities 11 (3) Comprehensive income $ 55 $ 150 Our financial statements are denominated in U.S. Dollars. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the three months ended March 30, 2024 and three months ended April 1, 2023 was primarily due to changes in foreign currency exchange rates of the Euro, Brazilian Real, British Pound, Australian Dollar, Swiss Franc and Canadian Dollar. The hedging gain (loss) during the three months ended March 30, 2024, and April 1, 2023 was attributable to a net investment hedge. The following table summarizes our total comprehensive income, net of applicable taxes as follows: Three Months Ended March 30, April 1, 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 60 $ 141 Comprehensive income attributable to noncontrolling interests 3 3 Comprehensive income (loss) attributable to Redeemable noncontrolling interests (8) 6 Comprehensive income $ 55 $ 150

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 30, 2024
Fair Value Measurements [Abstract]
Assets and Liabilities Measured and Recognized on a Recurring Basis	March 30, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total return swap - 1 - 1 Total assets $ - $ 4 $ - $ 4 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total liabilities $ - $ 2 $ - $ 2 Redeemable noncontrolling interests $ - $ - $ 798 $ 798 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return swap - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Debt - Schedule of Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 1,024	$ 1,074
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.00%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement Facilities 4 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement facilities 5 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities 6 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities 7 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033
Private Placement Facilities 8 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.79%
Debt Instrument, Maturity Date	May 04, 2028
Private Placement Facilities 9 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.84%
Debt Instrument, Maturity Date	May 04, 2030
Private Placement Facilities 10 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.96%
Debt Instrument, Maturity Date	May 04, 2033
Private Placement Facilities 11 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 150
Borrowing Rate	4.94%
Debt Instrument, Maturity Date	May 04, 2033

Significant Accounting Policies and Recently Issued Accounting Standards	3 Months Ended
	Mar. 30, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Significant Accounting Policies and Recently Issued Accounting Standards	Note 2 – Significant Accounting Policies and Recently Issued Accounting Standards Significant Accounting Policies There have been no material changes in our significant accounting policies during the three months ended March 30, 2024, as compared to the significant accounting policies described in Item 8 of our Annual Report on Form 10- K for the year ended December 30, 2023. Recently Issued Accounting Standards In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures ,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We do not expect that the requirements of ASU 2023 – 07 will have a material impact on our consolidated financial statements. In March 2024, the FASB issued ASU 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether a profit interest and similar awards should be accounted for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. The ASU provides an illustrative example with multiple fact patterns and amends the structure of paragraph 718-10-15-3 of Topic 718 to improve its clarity and operability. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. Entities can apply the amendments either retrospectively to all periods presented in the financial statements or prospectively to profits interest awards granted or modified on or after the date of adoption. If prospective application is elected, an entity must disclose the nature of and reason for the change in accounting principle that resulted from the adoption of the ASU. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. We do not expect that the requirements of ASU 2024 – 01 will have a material impact on our consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Net income attributable to redeemable noncontrolling interests	$ 2	$ 4	$ 6
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(10)	2	$ 5
Unrealized gain (loss) from foreign currency hedging activities, tax (benefit)	$ 4	$ (1)

Plan of Restructuring and Integration Costs (Tables)	3 Months Ended
Plan of Restructuring and Integration Costs (Tables)	Mar. 30, 2024
Plan of Restructuring [Abstract]
Schedule of Restructuring Costs and Integration Costs	Three Months Ended March 30, 2024 Health Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 6 $ 1 $ 7 Accelerated depreciation and amortization 1 - 1 Exit and other related costs 2 - 2 Total restructuring costs $ 9 $ 1 $ 10 Three Months Ended April 1, 2023 Health Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 17 $ 3 $ 20 Accelerated depreciation and amortization 7 - 7 Exit and other related costs 1 1 2 Loss on disposal of a business 1 - 1 Total restructuring costs $ 26 $ 4 $ 30
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2023 $ 22 $ 1 $ 23 Restructuring costs 9 1 10 Non-cash accelerated depreciation and amortization (1) - (1) Cash payments and other adjustments (11) (1) (12) Balance, March 30, 2024 $ 19 $ 1 $ 20

Plan of Restructuring - Schedule of Restructuring Reserve by Segment (Details) - USD ($)	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Restructuring Cost and Reserve [Line Items]
Balance, beginning	$ 23,000,000
Restructuring costs	10,000,000	$ 30,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	(1,000,000)
Cash payments and other adjustments	12,000,000
Balance, ending	20,000,000
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning	22,000,000
Restructuring costs	9,000,000	26,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	(1,000,000)
Cash payments and other adjustments	11,000,000
Balance, ending	19,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning	1,000,000
Restructuring costs	1,000,000	$ 4,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	0
Cash payments and other adjustments	1,000,000
Balance, ending	$ 1,000,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions

Mar. 30, 2024

Dec. 30, 2023

Current assets:

Cash and cash equivalents

$ 159

$ 171

Accounts receivable, net of allowance for credit losses of $84 and $83

^[1]

1,644

1,863

Inventories, net of reserves of $188 and $192

1,686

1,815

Prepaid expenses and other

589

639

Total current assets

4,078

4,488

Property and equipment, net

500

498

Operating lease right-of-use assets

314

325

Goodwill

3,835

3,875

Other intangibles, net

915

916

Investments and other

503

471

Total assets

10,145

10,573

Current liabilities:

Accounts payable

879

1,020

Bank credit lines

264

Current maturities of long-term debt

103

150

Operating lease liabilities

Accrued expenses:

Payroll and related

245

332

Taxes

143

137

Other

625

700

Total current liabilities

2,334

2,683

Long-term debt

^[1]

2,010

1,937

Deferred income taxes

Operating lease liabilities

266

310

Other liabilities

423

436

Total liabilities

5,110

5,420

Redeemable noncontrolling interests

798

864

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 1,000,000 shares authorized, none outstanding

Common stock, $0.01 par value, 480,000,000 shares authorized,128,480,909 outstanding on March 30, 2024 and 129,247,765 outstanding on December 30, 2023

Additional paid-in capital

Retained earnings

3,838

3,860

Accumulated other comprehensive loss

(239)

(206)

Total Henry Schein, Inc. stockholders' equity

3,600

3,655

Noncontrolling interests

637

634

Total stockholders' equity

4,237

4,289

Total liabilities, redeemable noncontrolling interests and stockholders' equity

$ 10,145

$ 10,573

[1]	Amounts presented include balances held by our consolidated variable interest entity (“VIE”). At March 30, 2024 and December 30, 2023, includes trade accounts receivable of $ 497 million and $ 284 million, respectively, and long-term debt of $ 300 million and $ 210 million, respectively.

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (42)		$ (32)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(232)		(188)
Unrealized loss from hedging activities	(2)		(13)
Pension adjustment loss	(5)		(5)
Accumulated other comprehensive loss	(239)		(206)
Total Accumulated other comprehensive loss	(282)		$ (239)
Components of Comprehensive Income
Net Income (loss)	98	$ 128
Foreign currency translation gain (loss)	(54)	25
Tax effect	0	0
Foreign currency translation gain (loss)	(54)	25
Unrealized gain (loss) from foreign currency hedging activities	15	(4)
Tax effect	(4)	1
Unrealized gain (loss) from foreign currency hedging activities	11	(3)
Comprehensive income	$ 55	$ 150

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,172	$ 3,060
Cost of sales	2,160	2,094
Gross profit	1,012	966
Operating expenses:
Selling, general and administrative	791	717
Depreciation and amortization	61	44
Restructuring costs	10	30
Operating income	150	175
Other income (expense):
Interest income	5	3
Interest expense	(30)	(14)
Other, net	2	(1)
Income before taxes, equity in earnings of affiliates and noncontrolling interests	127	163
Income taxes	(32)	(39)
Equity in earnings of affiliates, net of tax	3	4
Net income	98	128
Less: Net income attributable to noncontrolling interests	(5)	(7)
Net income attributable to Henry Schein, Inc.	$ 93	$ 121
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0.72	$ 0.92
Diluted (in dollars per share)	$ 0.72	$ 0.91
Weighted-average common shares outstanding:
Basic (in shares)	128,720,661	131,365,789
Diluted (in shares)	129,769,580	133,039,886

Debt - Term Loan Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 30, 2024	Dec. 30, 2023
Term Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt face amount	$ 750
Debt term (in years)	3 years
Long-term debt	$ 736	$ 741
Term Credit Agreement [Member] \| Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Derivative fixed interest rate	5.91%	5.79%
Term Credit Agreement [Member] \| Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	5.32%	5.36%
Debt instrument, basis spread on variable rate	1.47%	1.35%
Debt instrument, interest rate at period end	6.79%	6.71%
September 2024 through June 2026 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 9
September 2023 through June 2024 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 5

Legal Proceedings	3 Months Ended
Legal Proceedings	Mar. 30, 2024
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by DCH Health Care Authority, et al. in Alabama state court, which is currently set for a jury trial on July 8, 2024; the action filed by Mobile County Board of Health, et al. in Alabama state court, which has been set for a jury trial on August 12, 2024; and the action filed by Florida Health Sciences Center, Inc. (and 25 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in September 2025. Of Henry Schein’s 2023 net sales of approximately $ 12.3 billion, sales of opioids represented less than four-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October 2022 Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. On January 18, 2024, a putative class action was filed against the Company in the U.S. District Court for the Eastern District of New York (“EDNY”), Case No. 24-cv-387 (the “Cruz-Bermudez Action”), based on the October 2023 cyber incident described in On January 26, 2024, a second putative class action was filed against the Company based on the cyber incident, also in the EDNY, Case No. 24-cv-550 (the “Depperschmidt Action”). On February 12, 2024, the Depperschmidt Action was voluntarily dismissed without prejudice. On February 16, 2024, an amended complaint was filed in the Cruz-Bermudez Action with additional plaintiffs’ counsel from the Depperschmidt Action and an additional new plaintiff. Plaintiffs in the Cruz-Bermudez Action seek to represent a class of all individuals whose personally identifying information and personal health information was compromised by the incident. Plaintiffs generally claim to have been harmed by alleged actions and/or omissions by the Company in connection with the incident and that the Company made deceptive public statements regarding privacy and data protection. Plaintiffs assert a variety of claims seeking monetary damages, injunctive relief, costs and attorneys’ fees, and other related relief. On March 22, 2024, plaintiffs voluntarily withdrew two of their five causes of action. On April 8, 2024, the court denied the Company’s motion to dismiss the remaining claims. The case remains pending. We intend to defend ourselves vigorously against this action. Henry Schein, Inc. and its affiliate, North American Rescue, LLC (“NAR”), have been named as defendants in a qui tam lawsuit brought under the federal False Claims Act (“FCA”), in an action entitled Russ and Murphy ex rel. United States v. North American Rescue, LLC et al. ; Case No. 21-cv-04238, filed in the United States District Court for the Eastern District of Pennsylvania. The case was filed under seal in 2021 by two relators (Corey Russ and Chris Murphy) who worked for one of NAR’s competitors. Relators also name C-A-T Resources, LLC (“CAT-R”) as a defendant. CAT -R manufactures one of the products at issue in the case (the combat application tourniquet, or “CAT”). After the Department of Justice declined to intervene, the case was unsealed, and Relators filed their first amended complaint in November 2023. In response to motions to dismiss filed by Henry Schein, NAR and CAT- R, Relators requested and obtained leave to file their Second Amended Complaint on April 24, 2024. Relators’ FCA claims are based on allegations that NAR and Henry Schein made false representations and certifications in connection with, and sold and submitted false claims for payment to the federal government for, various medical products that Relators contend violated certain “Buy American” laws (e.g., the Berry Amendment and Trade Agreements Act of 1979) and/or were not properly sterilized as noted on the products’ packaging, and thus misbranded. These products include the CAT, syringes, compressed gauze, tracheostomy kits, hypothermia blankets, eye, ear, nose and throat kits, and trauma dressing. Relators allege Henry Schein controlled and supervised NAR’s alleged misconduct for a period of time. Relators seek three times the amount of damages to be proved at trial, statutory civil penalties, reasonable expenses, attorneys’ fees and costs, and prejudgment interest. We intend to defend ourselves vigorously against this action. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of March 30, 2024, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 30, 2024 USD ($) number	Dec. 30, 2023 USD ($)
U.S. Trade Accounts Receivable Securitization Expiring 2022 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0030
U.S. Trade Accounts Receivable Securitization Expiring 2022 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0035
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450
Long-term debt	$ 300	$ 210
Number of banks as agents for debt instrument \| number	2
U.S. Trade Accounts Receivable Securitization [Member] \| Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	5.47%	5.67%
Debt instrument, basis spread on variable rate	0.75%	0.75%
Debt instrument, variable rate basis at period end	6.22%	6.42%

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 30, 2024
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry Schein, Inc., and all of our controlled subsidiaries (“we”, “us” and “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 30, 2023 and with the information contained in our other publicly- available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2024. Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE’s creditors have recourse to us for losses on these trade accounts receivable. At March 30, 2024 and December 30, 2023, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 497 million and $ 284 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 300 million and $ 210 million, respectively.

Net Sales from Contracts with Customers (Tables)	3 Months Ended
Net Sales from Contracts with Customers (Tables)	Mar. 30, 2024
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended March 30, 2024 North America International Global Net sales: Health care distribution Dental $ 1,103 $ 811 $ 1,914 Medical 1,014 27 1,041 Total health care distribution 2,117 838 2,955 Technology and value-added services 189 28 217 Total net sales $ 2,306 $ 866 $ 3,172 Three Months Ended April 1, 2023 North America International Global Net sales: Health care distribution Dental $ 1,144 $ 754 $ 1,898 Medical 951 20 971 Total health care distribution 2,095 774 2,869 Technology and value-added services 166 25 191 Total net sales $ 2,261 $ 799 $ 3,060

Plan of Restructuring	3 Months Ended
Plan of Restructuring	Mar. 30, 2024
Plan of Restructuring [Abstract]
Plan of Restructuring	Note 10 – Plan of Restructuring On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. We revised our previous expectations of completion and we have extended this initiative through the end of 2024. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. During the three months ended March 30, 2024 and April 1, 2023, we recorded restructuring costs of $ 10 million and $ 30 million, respectively. The restructuring costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. Restructuring costs recorded for the three months ended March 30, 2024 and April 1, 2023, consisted of the following: Three Months Ended March 30, 2024 Health Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 6 $ 1 $ 7 Accelerated depreciation and amortization 1 - 1 Exit and other related costs 2 - 2 Total restructuring costs $ 9 $ 1 $ 10 Three Months Ended April 1, 2023 Health Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 17 $ 3 $ 20 Accelerated depreciation and amortization 7 - 7 Exit and other related costs 1 1 2 Loss on disposal of a business 1 - 1 Total restructuring costs $ 26 $ 4 $ 30 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the three months ended March 30, 2024. The remaining accrued balance of restructuring costs as of March 30, 2024, which primarily relates to severance and employee-related costs, is included in accrued expenses: other within our condensed consolidated balance sheets. Liabilities related to exited leased facilities are recorded within our current and non-current operating lease liabilities within our condensed consolidated balance sheets. Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2023 $ 22 $ 1 $ 23 Restructuring costs 9 1 10 Non-cash accelerated depreciation and amortization (1) - (1) Cash payments and other adjustments (11) (1) (12) Balance, March 30, 2024 $ 19 $ 1 $ 20

Supplemental Cash Flow Information (Tables)	3 Months Ended
Supplemental Cash Flow Information (Tables)	Mar. 30, 2024
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Three Months Ended March 30, April 1, 2024 2023 Interest $ 26 $ 13 Income taxes 21 21

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	2 years 8 months 12 days
Grants in period (in shares)	0
Total unrecognized compensation cost related to non-vested awards	$ 120.0
Expected life of options (years)	6 years
Pre-tax share-based compensation (Credit) expense	$ 8.0	$ 10.0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
Percentage of stock options vest per year	33.33%
Expiration period (in years)	10 years
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	4 years
Time-Based Restricted Stock/Restricted Units [Member] \| 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 75		$ 80
Noncurrent operating lease liabilities	266		310
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Other liabilities	6		5
Due from related party	31		32
Revenues	12	$ 8
Purchases from related party	3	2
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Other liabilities	$ 3		$ 1
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period covered by agreement	10 years
Related party agreement amount	$ 31
Operating costs and expenses	8	$ 8
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	5
Noncurrent operating lease liabilities	$ 22
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage	6.70%		6.30%
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Non-Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage	8.20%		7.40%
Employees and Minority Shareholders [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	1 month
Employees and Minority Shareholders [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	17 years

Fair Value Measurements - Assets and Liabilities Measured and Recognized on a Recurring Basis (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023	Dec. 31, 2022
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 798	$ 864	$ 576
Fair value, measurements, recurring [Member]
Assets [Abstract]
Total return swaps	1	4
Total assets	4	6
Liabilities [Abstract]
Total liabilities	2	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	798	864
Fair value, measurements, recurring [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	1	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	18
Fair value, measurements, recurring [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	2	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	2
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Total return swaps	1	4
Total assets	4	6
Liabilities [Abstract]
Total liabilities	2	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	1	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	18
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	2	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	2
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	798	864
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	$ 0	$ 0

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Asset Pledged as Collateral [Member]
Pledged assets	$ 497	$ 284
Recourse [Member]
Liabilities of VIE	$ 300	$ 210

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 30, 2024
Debt [Abstract]
Schedule of Bank Credit Lines	March 30, December 30, 2024 2023 Revolving credit agreement $ 50 $ 200 Other short-term bank credit lines 214 64 Total $ 264 $ 264
Schedule of Long-Term Debt	March 30, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 736 741 U.S. trade accounts receivable securitization 300 210 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2030 at interest rates from 0.00 % to 9.42 % at March 30, 2024 and from 0.00 % to 9.42 % at December 30, 2023 46 54 Finance lease obligations 7 8 Total 2,113 2,087 Less current maturities (103) (150) Total long-term debt $ 2,010 $ 1,937
Schedule of Private Placement Facility Borrowings	Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

Basis of Presentation (Policy)	3 Months Ended
Basis of Presentation (Policy)	Mar. 30, 2024
Basis of Presentation [Abstract]
Principles of Consolidation	Our condensed consolidated financial statements include the accounts of Henry Schein, Inc., and all of our controlled subsidiaries (“we”, “us” and “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2024.
Consolidated Variable Interest Entity	We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE’s creditors have recourse to us for losses on these trade accounts receivable. At March 30, 2024 and December 30, 2023, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 497 million and $ 284 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 300 million and $ 210 million, respectively.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 30, 2024 shares
Insider Trading Arr [Line Items]
Material Terms of Trading Arrangement	ITEM 5. OTHER INFORMATION Rule 10b5-1 Trading Arrangements During the three months ended March 30, 2024, (i) Michael S. Ettinger , the Company’s Executive Vice President and Chief Operating Officer , and (ii) Walter Siegel , the Company’s Senior Vice President and Chief Legal Officer , each adopted a Rule10b5-1 trading arrangement which is a trading plan for the future sale of securities that is intended to satisfy the affirmative defense of Exchange Act Rule 10b5 -1(c), as well as the requirements of the Company’s insider trading policy. Each plan is subject to an initial “cooling off” period during which there may be no transactions between the adoption date and a date that is the later of 90 days or two business days following the Company’s filing of its next quarterly report on Form 10-Q or Annual Report on form 10-K. On March 4, 2024 , Mr. Ettinger adopted the trading plan to sell a total of 12,240 shares based on limit orders at a specified price, with a term through March 4, 2025 . On March 7, 2024 , Mr. Siegel adopted the trading plan to sell 4,134 shares based on a limit order at a specified price, with a term through March 7, 2025 .
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael S. Ettinger [Member]
Insider Trading Arr [Line Items]
Name	Michael S. Ettinger
Title	Executive Vice President and Chief Operating Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 4, 2024
Termination Date	March 4, 2025
Aggregate Available	12,240
Walter Siegel [Member]
Insider Trading Arr [Line Items]
Name	Walter Siegel
Title	Senior Vice President and Chief Legal Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 7, 2024
Termination Date	March 7, 2025
Aggregate Available	4,134

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 864	$ 576	$ 576
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interest in subsidiaries	(94)		(19)
Increase in redeemable noncontrolling interests due to business acquisitions	0		326
Net income attributable to redeemable noncontrolling interests	2	4	6
Dividends declared, net of capital contributions	(6)		(19)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(10)	$ 2	5
Change in fair value of redeemable securities	42		(11)
Balance, end of period	$ 798		$ 864

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt (including bank credit lines)	$ 2,377	$ 2,351
Term Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt face amount	$ 750

Cybersecurity Incident - Narrative (Details) - Cyber Incident [Member] $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($)
Unusual or Infrequent Item, or Both [Line Items]
Expenses related to cybersecurity incident	$ 5
Cybersecurity Insurance Policy [Member]
Unusual or Infrequent Item, or Both [Line Items]
Insurance policy limitations	60
Insurance retention	$ 5

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 30, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 7 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Our investments and notes receivable fair value is based on Level 3 inputs within the fair value hierarchy. Debt The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is based on Level 3 inputs within the fair value hierarchy, and as of March 30, 2024 and December 30, 2023 was estimated at $ 2,377 million and $ 2,351 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. Our derivative instruments primarily include foreign currency forward agreements, forecasted inventory purchase commitments, foreign currency forward contracts, interest rate swaps and total return swaps. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which are based on market rates for comparable transactions that are classified within Level 2 of the fair value hierarchy. The fair value of the interest rate swap, which is classified within Level 2 of the fair value hierarchy, is determined by comparing our contract rate to a forward market rate as of the valuation date. The fair value of total return swaps is determined by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date that are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are based on recent transactions and/or implied multiples of earnings that are classified within Level 3 of the fair value hierarchy. Assets measured on a non-recurring basis at fair value include intangibles. Inputs for measuring intangibles are classified as Level 3 within the fair value hierarchy. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 30, 2024 and December 30, 2023: March 30, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total return swap - 1 - 1 Total assets $ - $ 4 $ - $ 4 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total liabilities $ - $ 2 $ - $ 2 Redeemable noncontrolling interests $ - $ - $ 798 $ 798 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return swap - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
Redeemable Noncontrolling Interests (Tables)	Mar. 30, 2024
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	March 30, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (94) (19) Increase in redeemable noncontrolling interests due to business acquisitions - 326 Net income attributable to redeemable noncontrolling interests 2 6 Distributions declared, net of capital contributions (6) (19) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests (10) 5 Change in fair value of redeemable securities 42 (11) Balance, end of period $ 798 $ 864

Plan of Restructuring - Schedule of Restructuring Costs and Integration Costs (Details) - USD ($)	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 10,000,000	$ 30,000,000
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	7,000,000	20,000,000
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000	7,000,000
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000	2,000,000
Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		1,000,000
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	9,000,000	26,000,000
Health Care Distribution [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	6,000,000	17,000,000
Health Care Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000	7,000,000
Health Care Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000	1,000,000
Health Care Distribution [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		1,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000	4,000,000
Technology and Value-Added Services [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000	3,000,000
Technology and Value-Added Services [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0	0
Technology and Value-Added Services [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 0	1,000,000
Technology and Value-Added Services [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 15 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended March 30, April 1, 2024 2023 Basic 128,720,661 131,365,789 Effect of dilutive securities: Stock options and restricted stock units 1,048,919 1,674,097 Diluted 129,769,580 133,039,886 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Three Months Ended March 30, April 1, 2024 2023 Stock options 419,139 422,190 Restricted stock units 245,667 18,305 Total anti-dilutive securities excluded from earnings per share computation 664,806 440,495

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Disaggregation of Revenue [Abstract]
Net sales	$ 3,172	$ 3,060
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,306	2,261
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	866	799
Health Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,955	2,869
Health Care Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,117	2,095
Health Care Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	838	774
Health Care Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,914	1,898
Health Care Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,103	1,144
Health Care Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	811	754
Health Care Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,041	971
Health Care Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,014	951
Health Care Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	27	20
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	217	191
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	189	166
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 28	$ 25

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Weighted-average common shares outstanding:
Basic (in shares)	128,720,661	131,365,789
Effect of dilutive securities:
Stock options and restricted stock units	1,048,919	1,674,097
Diluted (in shares)	129,769,580	133,039,886

Comprehensive Income (Tables)	3 Months Ended
Comprehensive Income (Tables)	Mar. 30, 2024
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	March 30, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (42) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (232) $ (188) Unrealized loss from hedging activities (2) (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (239) $ (206) Total Accumulated other comprehensive loss $ (282) $ (239)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended March 30, April 1, 2024 2023 Net income $ 98 $ 128 Foreign currency translation gain (loss) (54) 25 Tax effect - - Foreign currency translation gain (loss) (54) 25 Unrealized gain (loss) from hedging activities 15 (4) Tax effect (4) 1 Unrealized gain (loss) from hedging activities 11 (3) Comprehensive income $ 55 $ 150
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended March 30, April 1, 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 60 $ 141 Comprehensive income attributable to noncontrolling interests 3 3 Comprehensive income (loss) attributable to Redeemable noncontrolling interests (8) 6 Comprehensive income $ 55 $ 150

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Cash flows from operating activities:
Net income	$ 98	$ 128
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	73	52
Non-cash restructuring charges	1	7
Stock-based compensation expense	8	10
Provision for losses on trade and other accounts receivable	5	1
Provision for deferred income taxes	2	2
Equity in earnings of affiliates	(3)	(4)
Distributions from equity affiliates	2	2
Changes in unrecognized tax benefits	2	1
Other	(6)	(1)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	190	(20)
Inventories	74	63
Other current assets	41	29
Accounts payable and accrued expenses	(290)	(243)
Net cash provided by operating activities	197	27
Cash flows from investing activities:
Purchases of property and equipment	(41)	(31)
Payments related to equity investments and business acquisitions, net of cash acquired	(20)	(1)
Proceeds from loan to affiliate	1	2
Capitalized software costs	(9)	(9)
Other	(3)	0
Net cash used in investing activities	(72)	(39)
Cash flows from financing activities:
Net change in credit lines	0	132
Proceeds from issuance of long-term debt	90	31
Principal payments for long-term debt	(60)	(1)
Proceeds from issuance of stock upon exercise of stock options	1	1
Payments for repurchases and retirement of common stock	(75)	(100)
Payments for taxes related to shares withheld for employee taxes	(7)	(30)
Distributions to noncontrolling shareholders	(6)	(4)
Acquisitions of noncontrolling interests in subsidiaries	(94)	(8)
Net cash provided by (used in) financing activities	(151)	21
Effect of exchange rate changes on cash and cash equivalents	14	0
Net change in cash and cash equivalents	(12)	9
Cash and cash equivalents, beginning of period	171	117
Cash and cash equivalents, end of period	$ 159	$ 126

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	1,078,459
Exercised (in shares) \| shares	(21,570)
Forfeited (in shares) \| shares	(897)
Outstanding at end of period (in shares) \| shares	1,055,992
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 71.46
Exercised (in dollars per share) \| $ / shares	62.71
Forfeited (in dollars per share) \| $ / shares	82.62
Outstanding at end of period (in dollars per share) \| $ / shares	$ 71.63
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	7 years 3 months 18 days
Outstanding at end of period, Aggregate Intrinsic Value \| $	$ 8
Options exercisable (in shares) \| shares	908,836
Weighted average exercise price, options exercisable (in dollars per share) \| $ / shares	$ 69.49

Stock-Based Compensation - Status of Unvested RSUs (Details)	3 Months Ended
	Mar. 30, 2024 $ / shares shares
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,655,393
Granted (in shares) \| shares	432,350
Vested (in shares) \| shares	(307,839)
Forfeited (in shares) \| shares	(6,021)
Ending balance outstanding (in shares) \| shares	1,773,883
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 70.34
Granted (in dollars per share)	76.56
Vested (in dollars per share)	62.51
Forfeited (in dollars per share)	81.48
Ending balance outstanding (in dollars per share)	73.19
Aggregate intrinsic value	$ 75.52
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	208,742
Granted (in shares) \| shares	450,333
Vested (in shares) \| shares	(6,432)
Forfeited (in shares) \| shares	(6,431)
Ending balance outstanding (in shares) \| shares	646,212
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 78.02
Granted (in dollars per share)	76.81
Vested (in dollars per share)	63.01
Forfeited (in dollars per share)	83.07
Ending balance outstanding (in dollars per share)	75.68
Aggregate intrinsic value	$ 75.52

Debt - Other Short-Term Bank Credit Lines Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank credit lines	$ 264	$ 264
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	383	368
Bank credit lines	$ 214	$ 64
Weighted average interest rate on borrowings under credit lines at period end	6.08%	6.02%
Average amount outstanding	$ 96

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Income Tax Examination [Line Items]
Effective tax rate	25.60%	23.80%
Tax interest expense (credit)	$ 1	$ 1
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	113		$ 115
Unrecognized tax benefits that would affect the effective tax rate if recognized	106		107
Total interest	$ 17		$ 16

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	$ 0	$ 3,678	$ (233)	$ 649
Beginning Balance, shares (in shares) at Dec. 31, 2022		131,792,817
Net income (excluding amounts attributable to redeemable noncontrolling interests)	124			121		3
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	23				23
Unrealized gain from foreign currency hedging activities, net of tax	(3)				(3)
Change in fair value of redeemable securities	3		3
Initial noncontrolling interests and adjustments related to business acquisitions	3					3
Repurchases and retirement of common stock - Value	(100)		(13)	(87)
Repurchases and retirement of common stock - Shares		(1,223,919)
Stock-based compensation expense - Value	10		10
Stock-based compensation expense - Shares		1,016,300
Stock issued upon exercise of stock options - Value	1		1
Stock issued upon exercise of stock options - Shares		10,779
Shares withheld for payroll taxes - Value	(29)		(29)
Shares withheld for payroll taxes - Shares		(399,194)
Transfer of charges in excess of capital	0		28	(28)
Ending Balance at Apr. 01, 2023	4,127	$ 1	0	3,684	(213)	655
Ending Balance, shares (in shares) at Apr. 01, 2023		131,196,783
Beginning Balance at Dec. 30, 2023	$ 4,289	$ 1	0	3,860	(206)	634
Beginning Balance, shares (in shares) at Dec. 30, 2023	129,247,765	129,247,765
Net income (excluding amounts attributable to redeemable noncontrolling interests)	$ 96			93		3
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	(44)				(44)
Unrealized gain from foreign currency hedging activities, net of tax	11				11
Change in fair value of redeemable securities	(42)		(42)
Initial noncontrolling interests and adjustments related to business acquisitions	1		1
Repurchases and retirement of common stock - Value	(75)		(10)	(65)
Repurchases and retirement of common stock - Shares		(998,728)
Stock-based compensation expense - Value	8		8
Stock-based compensation expense - Shares		314,759
Stock issued upon exercise of stock options - Value	$ 1		1
Stock issued upon exercise of stock options - Shares	21,570	20,939
Shares withheld for payroll taxes - Value	$ (8)		(8)
Shares withheld for payroll taxes - Shares		(103,865)
Settlement of stock-based compensation awards - Value	0		0
Settlement of stock-based compensation awards - Shares		39
Transfer of charges in excess of capital	0		50	(50)
Ending Balance at Mar. 30, 2024	$ 4,237	$ 1	$ 0	$ 3,838	$ (239)	$ 637
Ending Balance, shares (in shares) at Mar. 30, 2024	128,480,909	128,480,909

Debt - Revolving Credit Agreement Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Aug. 20, 2021	Mar. 30, 2024	Dec. 30, 2023
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit initiation date	Aug. 20, 2021	Jul. 11, 2023
Credit facility borrowing capacity		$ 1,000
Credit facility expiration date		Jul. 11, 2028
Line of credit interest rate		5.32%
Debt instrument, basis spread on variable rate		1.10%
Line of credit combined interest rate		6.42%
Borrowings		$ 50	$ 200
Outstanding letters of credit provided to third parties		10	10
Average amount outstanding		100
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity		383	$ 368
Average amount outstanding		$ 96

Supplemental Cash Flow Information	3 Months Ended
Supplemental Cash Flow Information	Mar. 30, 2024
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 16 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Three Months Ended March 30, April 1, 2024 2023 Interest $ 26 $ 13 Income taxes 21 21 For the three months ended March 30, 2024 and April 1, 2023, we had $ 15 million and $ (4) million of non-cash net unrealized gains (losses) related to hedging activities, respectively.

Plan of Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 10	$ 30

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 98	$ 128
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)	(54)	25
Unrealized gain (loss) from foreign currency hedging activities	11	(3)
Other comprehensive income (loss), net of tax	(43)	22
Comprehensive income	55	150
Comprehensive income attributable to noncontrolling interests:
Net income	(5)	(7)
Foreign currency translation loss (gain)	10	(2)
Comprehensive loss (income) attributable to noncontrolling interests	5	(9)
Comprehensive income attributable to Henry Schein, Inc.	$ 60	$ 141

Segment Data (Details) $ in Millions	3 Months Ended
Segment Data (Details) $ in Millions	Mar. 30, 2024 USD ($) segments countries	Apr. 01, 2023 USD ($)
Segment Data [Abstract]
Number of reportable segments \| segments	2
Segment Reporting Information [Line Items]
Net sales	$ 3,172	$ 3,060
Operating income	150	175
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,955	2,869
Operating income	$ 126	145
Number of countries served globally \| countries	33
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,914	1,898
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	1,041	971
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	217	191
Operating income	$ 24	$ 30

Cyber Incident	3 Months Ended
Cyber Incident	Mar. 30, 2024
Cyber Incident [Abstract]
Cyber Incident	Note 3 – Cyber Incident In October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business, was not affected, and our manufacturing businesses were mostly unaffected. On November 22, 2023, we experienced a disruption of our ecommerce platform and related applications, which has since been remediated. During the three months ended March 30, 2024, we continued to experience a residual impact of the cyber events noted above relating primarily to decreased sales to episodic customers (customers that had generally registered a less continuous level of demand pre-incident). During the three months ended March 30, 2024, we incurred $ 5 million of expenses directly related to the cyber incident, mostly consisting of professional fees. We maintain cyber insurance, subject to certain retentions and policy limitations. With respect to the October 2023 cyber incident, we have a $ 60 million insurance policy, following a $ 5 million retention.

Debt	3 Months Ended
Debt	Mar. 30, 2024
Debt [Abstract]
Debt	Note 8 – Debt Bank Credit Lines Bank credit lines consisted of the following: March 30, December 30, 2024 2023 Revolving credit agreement $ 50 $ 200 Other short-term bank credit lines 214 64 Total $ 264 $ 264 Revolving Credit Agreement On August 20, 2021 , we entered a $ 1.0 billion revolving credit agreement (the “Revolving Credit Agreement”) which was subsequently amended and restated on July 11, 2023 to extend the maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market approach for a multicurrency facility. The interest rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter. As of March 30, 2024 the interest rate on this revolving credit agreement was 5.32 % plus 1.10 % for a combined rate of 6.42 %. The Revolving Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of March 30, 2024 and December 30, 2023, we had $ 50 million and $ 200 million in borrowings, respectively under this revolving credit facility. During the three months ended March 30, 2024, the average outstanding balance under the Revolving Credit Agreement was approximately $ 100 million. As of March 30, 2024 and December 30, 2023, there were $ 10 million and $ 10 million of letters of credit, respectively, provided to third parties under this Revolving Credit Agreement. Other Short-Term Bank Credit Lines As of March 30, 2024 and December 30, 2023, we had various other short-term bank credit lines available, in various currencies, with a maximum borrowing capacity of $ 383 million and $ 368 million, respectively. As of March 30, 2024 and December 30, 2023, $ 214 million and $ 64 million, respectively, were outstanding. During the three months ended March 30, 2024, the average outstanding balances under our various other short-term bank credit lines was approximately $ 96 million. At March 30, 2024 and December 30, 2023, borrowings under other short-term bank credit lines had weighted average interest rates of 6.08 % and 6.02 %, respectively. Long-term debt Long-term debt consisted of the following: March 30, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 736 741 U.S. trade accounts receivable securitization 300 210 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2030 at interest rates from 0.00 % to 9.42 % at March 30, 2024 and from 0.00 % to 9.42 % at December 30, 2023 46 54 Finance lease obligations 7 8 Total 2,113 2,087 Less current maturities (103) (150) Total long-term debt $ 2,010 $ 1,937 Private Placement Facilities Our private placement facilities include four insurance companies, have a total facility amount of $ 1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 . The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings, which have a weighted average interest rate of 3.66 %, as of March 30, 2024 are presented in the following table: Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024 Term Loan On July 11, 2023, we entered into a three-year $ 750 million term loan credit agreement (the “Term Credit Agreement”). The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. This term loan matures on July 11, 2026. We are required to make quarterly payments of $ 5 million from September 2023 through June 2024 and quarterly payments of $ 9 million from September 2024 through June 2026, with the remaining balance due in July 2026. As of March 30, 2024, the borrowings outstanding under this term loan were $ 736 million. At March 30, 2024, the interest rate under the Term Credit Agreement was 5.32 % plus 1.47 % for a combined rate of 6.79 %. As of December 30, 2023, the borrowings outstanding under this term loan were $ 741 million. At December 30, 2023, the interest rate under the Term Credit Agreement was 5.36 % plus 1.35 % for a combined rate of 6.71 %. However, we have a hedge in place that ultimately creates an effective fixed rate of 5.91 % and 5.79 % at March 30, 2024 and December 30, 2023, respectively. The Term Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. U.S. Trade Accounts Receivable Securitization We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . This facility agreement has a purchase limit of $ 450 million with two banks as agents, and expires on December 15, 2025 . As of March 30, 2024 and December 30, 2023, the borrowings outstanding under this securitization facility were $ 300 million and $ 210 million, respectively. At March 30, 2024, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.47 % plus 0.75 %, for a combined rate of 6.22 %. At December 30, 2023, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.67 % plus 0.75 %, for a combined rate of 6.42 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended
	Mar. 30, 2024	Jul. 01, 2023	Mar. 30, 2024	Dec. 30, 2023
Identifiable assets acquired and liabilities assumed:
Goodwill	$ 3,835		$ 3,835	$ 3,875
Biotech Dental [Member]
Acquisition consideration:
Cash		$ 216	216
Fair value of contributed equity share in a controlled subsidiary		25	25
Redeemable noncontrolling interests		182	182
Total consideration		423	423
Identifiable assets acquired and liabilities assumed:
Current assets	74	78	74
Intangible assets	189	119	189
Other noncurrent assets	69	76	69
Current liabilities	(60)	(50)	(60)
Long-term debt	(73)	(90)	(73)
Deferred income taxes	(53)	(38)	(53)
Other noncurrent liabilities	(20)	(16)	(20)
Total identifiable net assets	126	79	126
Goodwill	297	344	297
Total net assets acquired	423	$ 423	423
Biotech Dental [Member] \| Restatement Adjustment [Member]
Identifiable assets acquired and liabilities assumed:
Current assets	(4)		(4)
Intangible assets	70		70
Other noncurrent assets	(7)		(7)
Current liabilities	(10)		(10)
Long-term debt	17		17
Deferred income taxes	(15)		(15)
Other noncurrent liabilities	(4)		(4)
Total identifiable net assets	47		47
Goodwill	(47)		(47)
Total net assets acquired	0		0
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Cash	19
Identifiable assets acquired and liabilities assumed:
Intangible assets	12		12
Goodwill	$ 8		$ 8

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - Biotech Dental [Member] $ in Millions	Apr. 05, 2023 USD ($)
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 189
Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 47
Estimated useful lives (in years)	9 years
Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 18
Estimated useful lives (in years)	7 years
Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 124
Estimated useful lives (in years)	10 years

Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions

Mar. 30, 2024

Dec. 30, 2023

Debt Instrument [Line Items]

Finance lease obligations

$ 7

$ 8

Total

2,113

2,087

Less current maturities

(103)

(150)

Long-term debt

^[1]

2,010

1,937

Term Credit Agreement [Member]

Debt Instrument [Line Items]

Long-term debt

736

741

Private Placement Facilities [Member]

Debt Instrument [Line Items]

Long-term debt

1,024

1,074

U.S. Trade Accounts Receivable Securitization [Member]

Debt Instrument [Line Items]

Long-term debt

300

210

Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member]

Debt Instrument [Line Items]

Long-term debt

$ 46

$ 54

Debt Instrument [Line Items]

Borrowing Rate

0.00%

Debt Instrument [Line Items]

Borrowing Rate

9.42%

[1]	Amounts presented include balances held by our consolidated variable interest entity (“VIE”). At March 30, 2024 and December 30, 2023, includes trade accounts receivable of $ 497 million and $ 284 million, respectively, and long-term debt of $ 300 million and $ 210 million, respectively.

Significant Accounting Policies and Recently Issued Accounting Standards (Policy)	3 Months Ended
	Mar. 30, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Accounting Standard Adopted and Recently Issued Accounting Standards	Recently Issued Accounting Standards In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures ,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We do not expect that the requirements of ASU 2023 – 07 will have a material impact on our consolidated financial statements. In March 2024, the FASB issued ASU 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether a profit interest and similar awards should be accounted for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. The ASU provides an illustrative example with multiple fact patterns and amends the structure of paragraph 718-10-15-3 of Topic 718 to improve its clarity and operability. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. Entities can apply the amendments either retrospectively to all periods presented in the financial statements or prospectively to profits interest awards granted or modified on or after the date of adoption. If prospective application is elected, an entity must disclose the nature of and reason for the change in accounting principle that resulted from the adoption of the ASU. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. We do not expect that the requirements of ASU 2024 – 01 will have a material impact on our consolidated financial statements.

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	3 Months Ended
	Mar. 30, 2024 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate at period end	3.66%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Redeemable Noncontrolling Interests	3 Months Ended
Redeemable Noncontrolling Interests	Mar. 30, 2024
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 13 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the three months ended March 30, 2024 and the year ended December 30, 2023 are presented in the following table: March 30, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (94) (19) Increase in redeemable noncontrolling interests due to business acquisitions - 326 Net income attributable to redeemable noncontrolling interests 2 6 Distributions declared, net of capital contributions (6) (19) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests (10) 5 Change in fair value of redeemable securities 42 (11) Balance, end of period $ 798 $ 864

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions				3 Months Ended	6 Months Ended	9 Months Ended
	Oct. 02, 2023	Jul. 05, 2023	Apr. 05, 2023	Mar. 30, 2024	Jul. 01, 2023	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023
Business Acquisition [Line Items]
Goodwill				$ 3,835		$ 3,835	$ 3,875
Acquisition costs				$ 2		$ 2		$ 7
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired				100.00%		100.00%
Consideration paid				$ 19
Goodwill				8		$ 8
Intangible assets				12		12
Change in fair value of contingent consideration				15
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Intangible assets				$ 6		6
Estimated useful lives (in years)				10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Intangible assets				$ 4		4
Estimated useful lives (in years)				10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets				$ 1		1
Estimated useful lives (in years)				5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Intangible assets				$ 1		1
Estimated useful lives (in years)				5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired							51.00%
Series Of Individually Immaterial Business Acquisitions [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired							100.00%
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired	90.00%
Consideration paid	$ 307
Total consideration	366
Deferred consideration	22
Redeemable noncontrolling interests	$ 37
S.I.N. Implant System [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired		100.00%
Total consideration		$ 329
Biotech Dental [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired			57.00%
Consideration paid					$ 216	216
Goodwill				$ 297	344	297
Intangible assets				$ 189	119	189
Total consideration					423	423
Redeemable noncontrolling interests					$ 182	$ 182
Biotech Dental [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			9 years
Biotech Dental [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			10 years
Biotech Dental [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			7 years

Income Taxes	3 Months Ended
Income Taxes	Mar. 30, 2024
Income Taxes [Abstract]
Income Taxes	Note 9 – Income Taxes For the three months ended March 30, 2024 our effective tax rate was 25.6 %, compared to 23.8 % for the prior year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes and interest expense. The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two Model Rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two framework. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities. As of March 30, 2024, the impact of the Pillar Two Rules to our financial statements was immaterial. As we operate in jurisdictions which have adopted Pillar Two, we are continuing to analyze the implications to effectively manage the impact for 2024 and beyond. The total amount of unrecognized tax benefits, which are included in “other liabilities” within our condensed consolidated balance sheets, as of March 30, 2024 and December 30, 2023, was $ 113 million and $ 115 million, respectively, of which $ 106 million and $ 107 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2019. The tax years subject to examination by the IRS include years 2020 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination. The amount of tax interest expense included as a component of the provision for taxes was $ 1 million and $ 1 million for the three months ended March 30, 2024 and April 1, 2023, respectively. The total amount of accrued interest is included in “other liabilities,” and was $ 17 million as of March 30, 2024 and $ 16 million as of December 30, 2023. The amount of penalties accrued for during the periods presented were not material to our condensed consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 30, 2024
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,078,459 $ 71.46 Granted - - Exercised (21,570) 62.71 Forfeited (897) 82.62 Outstanding at end of period 1,055,992 $ 71.63 7.3 $ 8 Options exercisable at end of period 908,836 $ 69.49
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 147,110 $ 84.84 8.0 $ -
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 432,350 76.56 450,333 76.81 Vested (307,839) 62.51 (6,432) 63.01 Forfeited (6,021) 81.48 (6,431) 83.07 Outstanding at end of period 1,773,883 $ 73.19 $ 75.52 646,212 $ 75.68 $ 75.52

Segment Data	3 Months Ended
Segment Data	Mar. 30, 2024
Segment Data [Abstract]
Segment Data	Note 5 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices, and integrated delivery networks, among other providers across a wide range of specialties. Our dental and medical groups serve practitioners in 33 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) products, vitamins, and orthopedic implants. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. The following tables present information about our reportable and operating segments: Three Months Ended March 30, April 1, 2024 2023 Net sales: Health care distribution (1) Dental $ 1,914 $ 1,898 Medical 1,041 971 Total health care distribution 2,955 2,869 Technology and value-added services (2) 217 191 Total $ 3,172 $ 3,060 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins, and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended March 30, April 1, 2024 2023 Operating Income: Health care distribution $ 126 $ 145 Technology and value-added services 24 30 Total $ 150 $ 175

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 30, 2024	Apr. 29, 2024
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-28
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 30, 2024
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		128,050,943

Debt - Schedule of Bank Credit Lines (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank Credit lines	$ 264	$ 264
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	50	200
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 214	$ 64

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended		12 Months Ended
Legal Proceedings - Narrative (Details) $ in Millions	Mar. 30, 2024 USD ($) claims	Apr. 01, 2023 USD ($)	Dec. 30, 2023 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,172	$ 3,060
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage	0.40%
Actions Consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues			$ 12,300
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs	25

- Definition

+ References

+ Details

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 60	$ 141
Comprehensive income attributable to noncontrolling interests	3	3
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	(8)	6
Comprehensive income	$ 55	$ 150

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details